Loading clinical trials...

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure. | Clinical Trials | Clareo Health

TERMINATEDPHASE2

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.

A Phase 2 Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Ranging Study Of TBC3711 In Subjects With Resistant Hypertension

NCT00272961•Pfizer

View on ClinicalTrials.gov

Summary

The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.

Detailed Description

The study was stopped due to Pfizer (sponsor) decision that the compound would not be involved in any further clinical development for the indication of resistant hypertension on 05 August 2008. This decision was not based on any safety or efficacy concern.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of resistant hypertension.
•A stable anti-hypertensive drug regimen for at least 30 days.

Exclusion Criteria

•Sustained blood pressure greater than or equal to 180/120 mmHg.
•Required use of thigh cuff for blood pressure readings.
•Uncontrolled diabetes mellitus.

Locations (12)

Pfizer Investigational Site

Birmingham, Alabama, United States

Pfizer Investigational Site

Mobile, Alabama, United States

Pfizer Investigational Site

Atlanta, Georgia, United States

Pfizer Investigational Site

Augusta, Georgia, United States

Pfizer Investigational Site

Shreveport, Louisiana, United States

Pfizer Investigational Site

Albany, New York, United States

Pfizer Investigational Site

Oklahoma City, Oklahoma, United States

Pfizer Investigational Site

Simpsonville, South Carolina, United States

Pfizer Investigational Site

Germantown, Tennessee, United States

Pfizer Investigational Site

Carroltown, Texas, United States

Key Dates

Start Date

January 1, 2006

Primary Completion Date

August 1, 2008

Completion Date

August 1, 2008

Last Updated

March 5, 2013

Enrollment

ACTUAL participants

Conditions

Resistant Hypertension

Interventions

Placebo

DRUG

TBC3711

DRUG

TBC3711

DRUG

TBC3711

DRUG

TBC3711

DRUG

Endothelin-1 Receptor Blockade in Resistant Hypertension

NCT04388124

Resistant Hypertension

View study

RECRUITING

Symplicity China Study

NCT07081243

Resistant Hypertension

View study

RECRUITINGPHASE2

Endocalyx in Treatment Resistent Hypertension

NCT06940011

Treatment Resistant Hypertension

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.

Inclusion Criteria

Exclusion Criteria

Endothelin-1 Receptor Blockade in Resistant Hypertension

Symplicity China Study

Endocalyx in Treatment Resistent Hypertension

Evaluation of Two Isometric Exercises in the Reduction of the Blood Pressure in People With Resistant Hypertension

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.